Fluticasone furoate (FF) is an inhaled corticosteroid (ICS) with 24-hour activity in development as a once-daily treatment for the long-term management of asthma. This study assessed the efficacy of 4 doses of once-daily FF administered using a dry powder inhaler in patients older than 12 years with moderate asthma, uncontrolled on low-dose ICS (fluticasone propionate [FP] 200 μg/day or equivalent).
Fluticasone furoate is different in structure from fluticasone propionate (see below). Image source: Wikipedia, public domain.
Fluticasone propionate is part of the ICS/LABA combination product Advair. Image source: Wikipedia, public domain.
The study was double-blind, placebo-controlled, and randomized 600 patients. It was funded by the manufacturer, GlaxoSmithKline
At week 8, there was no evidence of a dose-response relationship between FF doses. Improvement with once-daily FF was similar to or greater than that for twice-daily FP. Oral candidiasis was reported in 0 to 4% of patients; 24-hour urinary cortisol excretion were similar to placebo.
FF 100 to 400 μg once daily in the evening was effective in patients with asthma uncontrolled on low-dose ICS, with 100 μg and 200 μg, considered the most applicable doses.
Editor’s note: The availability of another once-daily inhaled steroid (fluticasone furoate) will expand the treatment options for patients with asthma.
Once-daily fluticasone furoate is efficacious in patients with symptomatic asthma on low-dose inhaled corticosteroids. Eugene R. Bleecker et al. Annals of Allergy, Asthma & Immunology, Volume 109, Issue 5 , Pages 353-358.e4, November 2012.